4 results
The objective of the proposed study (1237.25) is to evaluate maximal treatment effect in FEV1 and SGRQ after 12-weeks treatment with two different doses of tiotropium + olodaterol FDC (5*g/ 5*g and 5*g/ 2.5*g) by comparison with placebo in patients…
The primary objective of this study is to evaluate the effects of two types of AR treatment & placebo in counteracting AR*s effects on Cognition and Driving. Therefore, the effects of nasal provocation in AR patients on cognitive functions…
The objective is to assess the feasibility and safety of the Qvanteq*s bioactive coronary Qstent for treatment of stable coronary artery disease patients with de novo coronary artery stenosis in native vessels.
The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 / 5 µg ; 5 / 5 µg) with tiotropium (5 µg), olodaterol (5 µg) and placebo on lung-hyperinflation and endurance time…